Why the study?
Does antiplatelet therapy non-response or resistance increase the risk of ischaemic events in patients with acute coronary syndromes?
Does antiplatelet therapy non-response or resistance increase the risk of ischaemic events in patients with acute coronary syndromes?
Answers are grounded in this paper and cite their sources.
This review highlights that while true 'aspirin resistance' is weakly supported, non-response to other antiplatelet agents like clopidogrel is clinically relevant and may require tailored therapy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Briasoulis et al. (2009) conducted a review in High risk for vascular events (n=140,000). Antiplatelet therapy was evaluated on Major vascular events.
Synapse has enriched 10 related papers. Consider them for comparative context: